CN114190362B - A kind of placenta preservation liquid and the preservation method of placenta - Google Patents
A kind of placenta preservation liquid and the preservation method of placenta Download PDFInfo
- Publication number
- CN114190362B CN114190362B CN202111495739.0A CN202111495739A CN114190362B CN 114190362 B CN114190362 B CN 114190362B CN 202111495739 A CN202111495739 A CN 202111495739A CN 114190362 B CN114190362 B CN 114190362B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- placenta
- traditional chinese
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000004321 preservation Methods 0.000 title abstract description 4
- 239000007788 liquid Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 96
- 239000000284 extract Substances 0.000 claims abstract description 75
- 239000003761 preservation solution Substances 0.000 claims abstract description 56
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 46
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims abstract description 46
- 241000218671 Ephedra Species 0.000 claims abstract description 37
- 241000202726 Bupleurum Species 0.000 claims abstract description 33
- 239000007853 buffer solution Substances 0.000 claims abstract description 24
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 23
- 108010024636 Glutathione Proteins 0.000 claims abstract description 23
- 229960005305 adenosine Drugs 0.000 claims abstract description 23
- 239000008103 glucose Substances 0.000 claims abstract description 23
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 23
- 229960005322 streptomycin Drugs 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 132
- 239000007864 aqueous solution Substances 0.000 claims description 47
- 238000000605 extraction Methods 0.000 claims description 24
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 2
- 239000012675 alcoholic extract Substances 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 30
- 230000004083 survival effect Effects 0.000 abstract description 8
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 229930182566 Gentamicin Natural products 0.000 abstract 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
- 229960002518 gentamicin Drugs 0.000 abstract 1
- 230000003169 placental effect Effects 0.000 description 35
- 230000000052 comparative effect Effects 0.000 description 27
- 230000003833 cell viability Effects 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 239000002994 raw material Substances 0.000 description 20
- 238000010828 elution Methods 0.000 description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012676 herbal extract Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004991 placental stem cell Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及医学技术领域,具体涉及一种胎盘保存液及胎盘的保存方法。The invention relates to the field of medical technology, in particular to a placenta preservation solution and a placenta preservation method.
背景技术Background technique
胎盘是胎儿与母体之间物质交换的重要器官,是人类妊娠期间由胚胎胚膜和母体子宫内膜联合长成的母子间组织结合器官。孕妇在生产后,胎盘就从身体上脱落。然而,离体的胎盘中含有大量的间充质干细胞;胎盘间充质干细胞(mesenchymal stem cell,MSC)是一种多能干细胞,是具有自我复制能力的多潜能细胞;如胎盘间充质干细胞在适宜的条件下分化为:上皮干细胞、神经干细胞、肝干细胞,肌细胞、成骨细胞、软骨细胞、基质细胞等多种细胞。其可以用来修复受损或病变的组织器官,治疗心脑血管疾病、神经系统疾病、肝脏疾病、骨组织病、角膜损伤、烧伤烫伤、肌病等多种疾病。The placenta is an important organ for material exchange between the fetus and the mother. It is a tissue-combining organ between the mother and the child formed by the joint growth of the embryonic embryonic membrane and the maternal endometrium during human pregnancy. After a pregnant woman gives birth, the placenta is released from the body. However, the isolated placenta contains a large number of mesenchymal stem cells; placental mesenchymal stem cells (mesenchymal stem cells, MSCs) are a kind of pluripotent stem cells, which are pluripotent cells with self-replication ability; such as placental mesenchymal stem cells Differentiate under suitable conditions: epithelial stem cells, neural stem cells, liver stem cells, muscle cells, osteoblasts, chondrocytes, stromal cells and other cells. It can be used to repair damaged or diseased tissues and organs, and treat cardiovascular and cerebrovascular diseases, nervous system diseases, liver diseases, bone tissue diseases, corneal injuries, burns, myopathy and other diseases.
但是,离体的胎盘中的胎盘间充质干细胞很快会失去活性;不利于后续胎盘间充质干细胞的分离培养。因此,提供一种能够使得离体的胎盘保持较高胎盘间充质干细胞活性的胎盘保存液具有重要的应用价值。However, the placental mesenchymal stem cells in the isolated placenta will soon lose their activity; it is not conducive to the subsequent isolation and culture of placental mesenchymal stem cells. Therefore, it is of great application value to provide a placenta preservation solution that can maintain a high activity of placental mesenchymal stem cells in an isolated placenta.
发明内容Contents of the invention
为了克服现有技术存在的至少之一的技术问题,本发明提供了一种胎盘保存液。In order to overcome at least one of the technical problems in the prior art, the present invention provides a placenta preservation solution.
本发明所要解决的上述技术问题,通过以下技术方案予以实现:The above-mentioned technical problems to be solved by the present invention are realized through the following technical solutions:
一种胎盘保存液,其包含如下重量份的组分:PBS缓冲液 100~150份;葡萄糖 3~5份;还原型谷胱苷肽 1~2份;腺苷 2~3份;链霉素 1~2份;大庆霉素 0.5~1份; 中药提取物 1~2份。A placenta preservation solution, which comprises the following components in parts by weight: 100-150 parts of PBS buffer solution; 3-5 parts of glucose; 1-2 parts of reduced glutathione; 2-3 parts of adenosine; streptomycin 1 to 2 parts; 0.5 to 1 part of Daqingmycin; 1 to 2 parts of traditional Chinese medicine extract.
发明人通过大量的实验研究表明,在上述组成的胎盘保存液中保存离体胎盘;可以使得胎盘中的胎盘间充质干细胞具有较高的存活率。The inventors have shown through a large number of experimental studies that the placental mesenchymal stem cells in the placenta can have a higher survival rate by preserving the isolated placenta in the above-mentioned placenta preservation solution.
优选地,所述的胎盘保存液,其包含如下重量份的组分:PBS缓冲液100~120份;葡萄糖 4~5份;还原型谷胱苷肽 1~1.5份;腺苷 2~2.5份;链霉素 1~1.5份;大庆霉素0.5~1份; 中药提取物 1~2份。Preferably, the placenta preservation solution comprises the following components in parts by weight: 100-120 parts of PBS buffer solution; 4-5 parts of glucose; 1-1.5 parts of reduced glutathione; 2-2.5 parts of adenosine ; Streptomycin 1 to 1.5 parts; Daqingmycin 0.5 to 1 part; Chinese medicine extract 1 to 2 parts.
优选地,所述的中药提取物通过如下步骤的方法制备得到:Preferably, the Chinese medicine extract is prepared by the following steps:
取中药麻黄和柴胡混合后用乙醇进行加热回流提取,提取结束后将提取液进行浓缩干燥得醇提物,即所述的中药提取物。The traditional Chinese medicine ephedra and bupleurum are mixed, and then heated and refluxed with ethanol for extraction. After the extraction, the extract is concentrated and dried to obtain an alcohol extract, which is the traditional Chinese medicine extract.
发明人在此需要说明的是,中药提取物的制备原料对于制备得到的中药提取物是否能有效地提高胎盘间充质干细胞的存活率起着决定性作用;在保存液中并不是随意加入中药提取物都能够提高胎盘间充质干细胞的存活率的。发明人通过大量实验表明,在胎盘保存液中加入由中药麻黄和柴胡为原料提取得到的中药提取物,可以有效地提高胎盘间充质干细胞的存活率。进一步研究表明:在胎盘保存液中加入由中药麻黄和柴胡为原料提取得到的中药提取物,其对胎盘间充质干细胞的存活率的提高程度远远高于加入单独以中药麻黄或柴胡其它中药为原料提取得到的中药提取物。What the inventor needs to explain here is that the raw materials for the preparation of Chinese medicine extracts play a decisive role in whether the prepared Chinese medicine extracts can effectively improve the survival rate of placental mesenchymal stem cells; All drugs can improve the survival rate of placental mesenchymal stem cells. The inventors have shown through a large number of experiments that adding traditional Chinese medicine extracts extracted from traditional Chinese medicines ephedra and Bupleurum chinensis into the placental preservation solution can effectively improve the survival rate of placental mesenchymal stem cells. Further studies have shown that adding traditional Chinese medicine extracts extracted from Chinese medicines Ephedra and Bupleurum to the placental preservation solution can improve the survival rate of placental mesenchymal stem cells much more than adding Chinese medicines such as ephedra or Bupleurum alone. Other traditional Chinese medicines are Chinese medicine extracts extracted from raw materials.
优选地,所述的乙醇选用的是体积分数为30%~50%的乙醇水溶液。Preferably, the ethanol is an aqueous ethanol solution with a volume fraction of 30% to 50%.
最优选地,所述的乙醇选用的是体积分数为40%的乙醇水溶液。Most preferably, the ethanol is an aqueous ethanol solution with a volume fraction of 40%.
优选地,中药麻黄和柴胡的重量比为3~5:1。Preferably, the weight ratio of the traditional Chinese medicine ephedra and Bupleuri is 3-5:1.
最优选地,中药麻黄和柴胡的重量比为4:1。Most preferably, the weight ratio of the traditional Chinese medicine Ephedra and Bupleurum is 4:1.
优选地,中药麻黄和柴胡的总重量与乙醇的用量比为1g:10~20mL。Preferably, the ratio of the total weight of the traditional Chinese medicine ephedra and Bupleuri to ethanol is 1g:10-20mL.
最优选地,中药麻黄和柴胡的总重量与乙醇的用量比为1g:15mL。Most preferably, the ratio of the total weight of the traditional Chinese medicine Ephedra and Bupleurum to the ethanol is 1g:15mL.
优选地,所述的加热回流提取是指在加热至乙醇沸腾的条件下进行回流提取1~2h。Preferably, the heating to reflux extraction refers to reflux extraction under the condition of heating to ethanol boiling for 1-2 hours.
进一步地,将醇提物上大孔树脂柱;先用体积分数为3%~5%的乙醇水溶液洗脱除杂;再用体积分数为16%~20%的乙醇水溶液洗脱,收集体积分数为16%~20%的乙醇水溶液洗脱下来的流份,浓缩干燥后即得所述的中药提取物。Further, put the ethanol extract on a macroporous resin column; first elute with an aqueous ethanol solution with a volume fraction of 3% to 5% to remove impurities; then elute with an aqueous ethanol solution with a volume fraction of 16% to 20%, and collect the volume fraction The fractions eluted with 16%-20% ethanol aqueous solution are concentrated and dried to obtain the traditional Chinese medicine extract.
优选地,先用2~4倍柱体积的体积分数为3%~5%的乙醇水溶液洗脱除杂;再用3~6倍柱体积的体积分数为16%~20%的乙醇水溶液洗脱,收集体积分数为16%~20%的乙醇水溶液洗脱下来的流份,浓缩干燥后即得所述的中药提取物。Preferably, first use 2 to 4 times column volume of ethanol water solution with a volume fraction of 3% to 5% to remove impurities; , collect the fractions eluted with ethanol aqueous solution with a volume fraction of 16% to 20%, concentrate and dry to obtain the Chinese medicine extract.
发明人进一步研究表明:在保存液中加入由上述大孔树脂柱层析方法制备得到的中药提取物,其对胎盘间充质干细胞的存活率有着进一步地大幅提高。Further studies by the inventors have shown that adding the traditional Chinese medicine extract prepared by the macroporous resin column chromatography method to the preservation solution can further greatly improve the survival rate of placental mesenchymal stem cells.
本发明还提供一种胎盘的保存方法,其包含如下步骤:将新鲜采集的胎盘浸泡在上述胎盘保存液中,并于0~5℃下进行保存。The present invention also provides a method for preserving the placenta, which comprises the following steps: soaking the freshly collected placenta in the above-mentioned placenta preserving solution, and preserving at 0-5°C.
有益效果:本发明提供了一种全新组成的胎盘保存液,该胎盘保存液通过加入了由中药麻黄和柴胡为原料提取得到的中药提取物,其可以有效地提高胎盘间充质干细胞的存活率。Beneficial effects: the present invention provides a brand-new placental preservation solution, which can effectively improve the survival of placental mesenchymal stem cells by adding the traditional Chinese medicine extract extracted from the traditional Chinese medicine ephedra and Bupleuri. Rate.
具体实施方式Detailed ways
以下结合具体实施例对本发明做进一步详细的说明,但实施例对本发明不做任何形式的限定。The present invention will be described in further detail below in conjunction with specific examples, but the examples do not limit the present invention in any form.
以下实施例中的PBS缓冲液通过如下方法制备得到:称取8.0g NaCl、0.2gKCl、1.44g Na2HPO4、0.24g KH2PO4溶于800mL蒸馏水中,用HCl调节溶液至7.4,最后加蒸馏水定容至1L即可得0.01M PBS缓冲液。The PBS buffer solution in the following examples was prepared by the following method: Weigh 8.0g NaCl, 0.2gKCl, 1.44g Na 2 HPO 4 , 0.24g KH 2 PO 4 and dissolve them in 800mL distilled water, adjust the solution to 7.4 with HCl, and finally Add distilled water to make up to 1L to get 0.01M PBS buffer.
实施例1胎盘保存液的制备The preparation of embodiment 1 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份; 中药提取物 1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得所述的中药提取物;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the traditional Chinese medicine Extract;
其中,中药麻黄和柴胡的重量比为4:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:15mL。Wherein, the weight ratio of the traditional Chinese medicine ephedra and Bupleurum is 4:1; the dosage ratio of the total weight of the traditional Chinese medicine ephedra and Bupleurum to the ethanol aqueous solution is 1g:15mL.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
实施例2胎盘保存液的制备The preparation of embodiment 2 placenta preservation solution
原料重量份组成:PBS缓冲液 150份;葡萄糖 5份;还原型谷胱苷肽 1份;腺苷 2.5份;链霉素 1份;大庆霉素 0.5份; 中药提取物 2份;Composition of raw materials by weight: 150 parts of PBS buffer solution; 5 parts of glucose; 1 part of reduced glutathione; 2.5 parts of adenosine; 1 part of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为30%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1h;提取结束后将提取液进行浓缩干燥,即得所述的中药提取物;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 30%, and carry out reflux extraction for 1 hour under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the Chinese medicine extract thing;
其中,中药麻黄和柴胡的重量比为3:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:10mL。Wherein, the weight ratio of the traditional Chinese medicine ephedra and bupleurum is 3:1; the dosage ratio of the total weight of the traditional Chinese medicine ephedra and bupleurum to the ethanol aqueous solution is 1g:10mL.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
实施例3胎盘保存液的制备The preparation of embodiment 3 placenta preservation solution
原料重量份组成:PBS缓冲液 100份;葡萄糖 3份;还原型谷胱苷肽 1份;腺苷 2份;链霉素 1份;大庆霉素 0.5份; 中药提取物 1份;Composition of raw materials by weight: 100 parts of PBS buffer solution; 3 parts of glucose; 1 part of reduced glutathione; 2 parts of adenosine; 1 part of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为50%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取2h;提取结束后将提取液进行浓缩干燥,即得所述的中药提取物;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 50%, and carry out reflux extraction for 2 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the Chinese medicine extract thing;
其中,中药麻黄和柴胡的重量比为5:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:20mL。Wherein, the weight ratio of the traditional Chinese medicine ephedra and Bupleurum is 5:1; the dosage ratio of the total weight of the traditional Chinese medicine ephedra and Bupleurum to the ethanol aqueous solution is 1g:20mL.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
实施例4胎盘保存液的制备The preparation of embodiment 4 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份; 中药提取物 1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得醇提物;其中,中药麻黄和柴胡的重量比为4:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:15mL;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the alcohol extract; Wherein, the weight ratio of Chinese medicine Ephedra and Bupleurum is 4:1; the consumption ratio of the total weight of Chinese medicine Ephedra and Bupleurum to ethanol aqueous solution is 1g:15mL;
进一步将醇提物上大孔树脂柱(其中装填有型号为HP-20的大孔树脂;大孔树脂的重量用量为醇提物重量的30倍);先用3倍柱体积的体积分数为4%的乙醇水溶液洗脱除杂;再用5倍柱体积的体积分数为18%的乙醇水溶液洗脱,收集体积分数为18%的乙醇水溶液洗脱下来的流份,浓缩干燥后即得所述的中药提取物。Further macroporous resin column (wherein packing is equipped with the macroporous resin that model is HP-20 with alcohol extract; The weight consumption of macroporous resin is 30 times of alcohol extract weight); 4% ethanol aqueous solution elution removes impurity; Then use 5 times column volume volume fraction to be 18% ethanol aqueous solution elution, collect the flow part that the volume fraction is 18% ethanol aqueous solution elution, get final product after concentrating and drying Chinese herbal extracts.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
实施例4与实施例1的区别在于,所述的中药提取物进一步通过大孔树脂柱制备得到。The difference between Example 4 and Example 1 is that the Chinese medicine extract is further prepared through a macroporous resin column.
对比例1胎盘保存液的制备Preparation of comparative example 1 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份;Composition in parts by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素以及大庆霉素加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin and dakinycin into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
对比例1与实施例1的区别在于,对比例1所述的胎盘保存液中不加入中药提取物。The difference between Comparative Example 1 and Example 1 is that no traditional Chinese medicine extract is added to the placenta preservation solution described in Comparative Example 1.
对比例2胎盘保存液的制备Preparation of comparative example 2 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份; 中药提取物 1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得所述的中药提取物;Take the traditional Chinese medicine ephedra, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the traditional Chinese medicine extract;
其中,中药麻黄与乙醇水溶液的用量比为1g:15mL。Wherein, the consumption ratio of traditional Chinese medicine ephedra and ethanol aqueous solution is 1g:15mL.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
对比例2与实施例1的区别在于,中药提取物的制备原料不同;对比例2仅仅以中药麻黄为原料制备得中药提取物;而实施例1则是以中药麻黄和柴胡为原料制备中药提取物。The difference between Comparative Example 2 and Example 1 is that the raw materials for the preparation of Chinese medicine extracts are different; Comparative Example 2 only uses the Chinese medicine Ephedra as raw material to prepare the Chinese medicine extract; while Example 1 uses the Chinese medicine Mahuang and Bupleurum as raw materials to prepare Chinese medicine Extract.
对比例3胎盘保存液的制备Preparation of comparative example 3 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷2份;链霉素1.5份;大庆霉素0.5份;中药提取物1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药柴胡,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得所述的中药提取物;Take the traditional Chinese medicine Bupleurum bupleuri, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the traditional Chinese medicine extract;
其中,中药柴胡与乙醇水溶液的用量比为1g:15mL。Wherein, the dosage ratio of the traditional Chinese medicine Bupleurum bupleuri and the ethanol aqueous solution is 1g:15mL.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
对比例3与实施例1的区别在于,中药提取物的制备原料不同;对比例2仅仅以中药柴胡为原料制备得中药提取物;而实施例1则是以中药麻黄和柴胡为原料制备中药提取物。The difference between Comparative Example 3 and Example 1 is that the raw materials for the preparation of Chinese medicine extracts are different; Comparative Example 2 only uses the traditional Chinese medicine Bupleuri as raw material to prepare the Chinese medicine extract; while Example 1 uses the Chinese medicine Ephedra and Bupleurum as raw materials. Chinese herbal extracts.
对比例4胎盘保存液的制备Preparation of comparative example 4 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份; 中药提取物 1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得醇提物;其中,中药麻黄和柴胡的重量比为4:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:15mL;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the alcohol extract; Wherein, the weight ratio of Chinese medicine Ephedra and Bupleurum is 4:1; the consumption ratio of the total weight of Chinese medicine Ephedra and Bupleurum to ethanol aqueous solution is 1g:15mL;
进一步将醇提物上大孔树脂柱(其中装填有型号为HP-20的大孔树脂;大孔树脂的重量用量为醇提物重量的30倍);先用3倍柱体积的水洗脱除杂;再用5倍柱体积的体积分数为8%的乙醇水溶液洗脱,收集体积分数为8%的乙醇水溶液洗脱下来的流份,浓缩干燥后即得所述的中药提取物。Further the ethanol extract is put on the macroporous resin column (which is filled with the macroporous resin of HP-20; the weight consumption of the macroporous resin is 30 times of the ethanol extract weight); Miscellaneous; Then use 5 times column volume volume fraction to be 8% ethanol aqueous solution elution, collect the flow part that the volume fraction is 8% ethanol aqueous solution elution, promptly obtain described Chinese medicine extract after concentrating and drying.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
对比例4与实施例4的区别在于,大孔树脂柱的洗脱条件不同;对比例4先用水洗脱除杂,再用体积分数为8%的乙醇水溶液洗脱;而实施例4则是先用体积分数为4%的乙醇水溶液洗脱除杂,再用体积分数为18%的乙醇水溶液洗脱。The difference between Comparative Example 4 and Example 4 is that the elution conditions of the macroporous resin column are different; Comparative Example 4 is first eluted with water to remove impurities, and then eluted with an aqueous ethanol solution with a volume fraction of 8%; while Example 4 is First use 4% ethanol aqueous solution to remove impurities, and then use 18% ethanol aqueous solution to elute.
对比例5胎盘保存液的制备Preparation of comparative example 5 placenta preservation solution
原料重量份组成:PBS缓冲液 120份;葡萄糖 4份;还原型谷胱苷肽 1.5份;腺苷 2份;链霉素 1.5份;大庆霉素 0.5份; 中药提取物 1.5份;Composition by weight of raw materials: 120 parts of PBS buffer solution; 4 parts of glucose; 1.5 parts of reduced glutathione; 2 parts of adenosine; 1.5 parts of streptomycin;
所述的中药提取物通过如下方法制备得到:The Chinese medicine extract is prepared by the following method:
取中药麻黄和柴胡混合后,加入体积分数为40%的乙醇水溶液,在加热至乙醇水溶液沸腾的条件下进行回流提取1.5h;提取结束后将提取液进行浓缩干燥,即得醇提物;其中,中药麻黄和柴胡的重量比为4:1;中药麻黄和柴胡的总重量与乙醇水溶液的用量比为1g:15mL;After mixing the traditional Chinese medicine ephedra and bupleurum, add ethanol aqueous solution with a volume fraction of 40%, and carry out reflux extraction for 1.5 hours under the condition of heating the ethanol aqueous solution to boiling; after the extraction is completed, the extract is concentrated and dried to obtain the alcohol extract; Wherein, the weight ratio of Chinese medicine Ephedra and Bupleurum is 4:1; the consumption ratio of the total weight of Chinese medicine Ephedra and Bupleurum to ethanol aqueous solution is 1g:15mL;
进一步将醇提物上大孔树脂柱(其中装填有型号为HP-20的大孔树脂;大孔树脂的重量用量为醇提物重量的30倍);先用3倍柱体积的体积分数为20%的乙醇水溶液洗脱除杂;再用5倍柱体积的体积分数为40%的乙醇水溶液洗脱,收集体积分数为40%的乙醇水溶液洗脱下来的流份,浓缩干燥后即得所述的中药提取物。Further macroporous resin column (wherein packing is equipped with the macroporous resin that model is HP-20 with alcohol extract; The weight consumption of macroporous resin is 30 times of alcohol extract weight); 20% ethanol aqueous solution for elution and impurity removal; then use 5 times of the column volume for eluting with 40% ethanol aqueous solution, collect the fractions eluted with 40% ethanol aqueous solution, concentrate and dry to obtain the obtained Chinese herbal extracts.
制备方法:将葡萄糖、还原型谷胱苷肽、腺苷、链霉素、大庆霉素以及中药提取物加入到PBS缓冲液中,搅拌均匀后即得所述的胎盘保存液。Preparation method: Add glucose, reduced glutathione, adenosine, streptomycin, dakinmycin and traditional Chinese medicine extracts into PBS buffer solution, stir evenly to obtain the placenta preservation solution.
对比例5与实施例4的区别在于,大孔树脂柱的洗脱条件不同;对比例5先用体积分数为20%的乙醇水溶液洗脱除杂,再用体积分数为40%的乙醇水溶液洗脱;而实施例4则是先用体积分数为4%的乙醇水溶液洗脱除杂,再用体积分数为18%的乙醇水溶液洗脱。The difference between Comparative Example 5 and Example 4 is that the elution conditions of the macroporous resin column are different; Comparative Example 5 is eluted with 20% ethanol aqueous solution to remove impurities, and then washed with 40% ethanol aqueous solution. and the embodiment 4 is firstly eluted with 4% ethanol aqueous solution to remove impurities, and then eluted with 18% ethanol aqueous solution.
实验例Experimental example
将新鲜采集的胎盘分别放入装有实施例1~3以及对比例1~5制备得到的胎盘保存液的胎盘采集盒中浸泡,胎盘保存液的用量为浸没胎盘;并于4℃下进行保存7天;然后分离胎盘间充质干细胞。Put the freshly collected placenta into the placenta collection boxes equipped with the placenta preservation solutions prepared in Examples 1-3 and Comparative Examples 1-5, respectively, and soak them in the amount of the placenta preservation solution to submerge the placenta; and store them at 4°C 7 days; then isolated placental mesenchymal stem cells.
将刚分离出来的胎盘干细胞,调整至密度为1×106cells/mL的细胞悬液;然后加入0.4%的台盼蓝染色液,混合均匀;再取加入台盼蓝染色液的细胞悬液20μL,加入到细胞计数板中,用Countstar细胞计数器进行细胞活率检测;细胞活率检测结果见表1。Adjust the freshly isolated placental stem cells to a cell suspension with a density of 1×10 6 cells/mL; then add 0.4% trypan blue staining solution and mix well; then take the cell suspension with trypan blue staining solution 20 μL was added to a cell counting plate, and the cell viability was detected with a Countstar cell counter; the results of the cell viability detection are shown in Table 1.
表1.细胞活率检测结果Table 1. Cell viability detection results
从表1细胞活率检测结果可以看出,将离体的胎盘保存在实施例1~4制备得到的胎盘保存液中7天后,其中的胎盘间充质干细胞的细胞活率均在72%以上;远远高于保存在对比例1不加入中药提取物的胎盘保存液中细胞活率。这说明:在胎盘保存液中加入由中药麻黄和柴胡为原料提取得到的中药提取物,可以大幅提高胎盘间充质干细胞的细胞活率。It can be seen from the test results of cell viability in Table 1 that after 7 days after the isolated placenta was stored in the placenta preservation solution prepared in Examples 1-4, the cell viability of the placental mesenchymal stem cells was above 72%. ; Much higher than the cell viability preserved in the placental preservation solution in Comparative Example 1 without adding the Chinese medicine extract. This shows that the addition of traditional Chinese medicine extracts extracted from the traditional Chinese medicine ephedra and Bupleurum chinensis as raw materials in the placental preservation solution can greatly increase the cell viability of placental mesenchymal stem cells.
从表1细胞活率检测结果还可以看出,将离体的胎盘保存在实施例4制备得到的胎盘保存液中7天后,其中的胎盘间充质干细胞的细胞活率均达94.45%,与保存在实施例1制备得到的胎盘保存液中相比,有着进一步地大幅提高;这说明:中药提取物进一步经本发明所述的上述大孔树脂柱层析方法处理,可以进一步富集大量的有效成分,进一步大幅提高了胎盘间充质干细胞的细胞活率。It can also be seen from the cell viability detection results in Table 1 that after the isolated placenta was stored in the placenta preservation solution prepared in Example 4 for 7 days, the cell viability of the placental mesenchymal stem cells in it all reached 94.45%, which was the same as Compared with the placental preservation solution prepared in Example 1, there is a further significant improvement; this illustrates: the Chinese medicine extract is further processed by the above-mentioned macroporous resin column chromatography method of the present invention, and can further enrich a large amount of The active ingredients further significantly increased the cell viability of placental mesenchymal stem cells.
从表1细胞活率检测结果还可以看出,将离体的胎盘保存在对比例2和3制备得到的胎盘保存液中7天后,其中的胎盘间充质干细胞的细胞活率与对比例1相比虽有提升,但是幅度不大;远远小于实施例1相对于对比例1的提升幅度。这说明:中药提取物的制备原料对于制备得到的中药提取物是否能有效地提高胎盘间充质干细胞的细胞活率起着决定性作用;在保存液中并不是随意加入中药提取物都能够大幅提高胎盘间充质干细胞的细胞活率的;在胎盘保存液中必须加入由中药麻黄和柴胡为原料提取得到的中药提取物,才能大幅提高胎盘间充质干细胞的细胞活率。It can also be seen from the cell viability detection results in Table 1 that after the isolated placenta was stored in the placental preservation solution prepared in Comparative Examples 2 and 3 for 7 days, the cell viability of the placental mesenchymal stem cells therein was the same as that in Comparative Example 1. Although there is improvement compared, the magnitude is not large; far less than the magnitude of promotion of Example 1 relative to Comparative Example 1. This shows that the raw materials for the preparation of Chinese medicine extracts play a decisive role in whether the prepared Chinese medicine extracts can effectively improve the cell viability of placental mesenchymal stem cells; The cell viability of placental mesenchymal stem cells must be added to the placental preservation solution to add Chinese medicine extracts extracted from the traditional Chinese medicine ephedra and Bupleuri as raw materials, in order to greatly increase the cell viability of placental mesenchymal stem cells.
从表1细胞活率检测结果还可以看出,将离体的胎盘保存在对比例4制备得到的胎盘保存液中7天后,其中的胎盘间充质干细胞的细胞活率与实施例1相比,提升得并不明显,其提升幅度远远小于实施例4;此外,将离体的胎盘保存在对比例5制备得到的胎盘保存液中7天后,其中的胎盘间充质干细胞的细胞活率与实施例1相比,还有所降低了;这说明:大孔树脂的洗脱条件对于能否制备得到具有更好的提高胎盘间充质干细胞的细胞活率的中药提取物起着决定性作用;只有在本发明所述的大孔树脂洗脱条件下(即先用体积分数为3%~5%的乙醇水溶液洗脱除杂;再用体积分数为16%~20%的乙醇水溶液洗脱,收集体积分数为16%~20%的乙醇水溶液洗脱下来的流份)制备得到的中药提取物才能进一步大幅提高胎盘间充质干细胞的细胞活率;而在其它大孔树脂洗脱条件下制备得到的中药提取物并不能进一步大幅提高胎盘间充质干细胞的细胞活率,甚至还降低了胎盘间充质干细胞的细胞活率。It can also be seen from the cell viability detection results in Table 1 that after 7 days after the isolated placenta was stored in the placenta preservation solution prepared in Comparative Example 4, the cell viability of the placental mesenchymal stem cells therein was compared with that of Example 1 , the promotion was not obvious, and its promotion range was far less than that of Example 4; in addition, after the isolated placenta was stored in the placenta preservation solution prepared in Comparative Example 5 for 7 days, the cell viability of the placental mesenchymal stem cells therein Compared with Example 1, it has also been reduced; this illustrates: the elution condition of macroporous resin plays a decisive role in whether the Chinese medicine extract with better cell viability of improving placental mesenchymal stem cells can be prepared ; Only under the macroporous resin elution conditions described in the present invention (i.e. first use volume fraction is 3% ~ 5% ethanol aqueous solution elution to remove impurities; then use volume fraction is 16% ~ 20% ethanol aqueous solution elution , collecting the fractions eluted with ethanol aqueous solution with a volume fraction of 16% to 20%), the prepared Chinese medicine extract can further greatly improve the cell viability of placental mesenchymal stem cells; while under other macroporous resin elution conditions The prepared traditional Chinese medicine extract can not further significantly increase the cell viability of the placental mesenchymal stem cells, and even reduces the cell viability of the placental mesenchymal stem cells.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111495739.0A CN114190362B (en) | 2021-12-08 | 2021-12-08 | A kind of placenta preservation liquid and the preservation method of placenta |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111495739.0A CN114190362B (en) | 2021-12-08 | 2021-12-08 | A kind of placenta preservation liquid and the preservation method of placenta |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114190362A CN114190362A (en) | 2022-03-18 |
CN114190362B true CN114190362B (en) | 2023-03-21 |
Family
ID=80651463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111495739.0A Active CN114190362B (en) | 2021-12-08 | 2021-12-08 | A kind of placenta preservation liquid and the preservation method of placenta |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114190362B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644167A (en) * | 2022-11-01 | 2023-01-31 | 江西省科学院生物资源研究所 | Placenta tissue preserving fluid and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201738373A (en) * | 2016-04-29 | 2017-11-01 | Ultra-Microrigin Biomedical Technology Co Ltd | Placenta active component preparation method for increasing survival rate of stem cells capable of increasing the survival rate of stem cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100540012C (en) * | 2005-07-25 | 2009-09-16 | 郭爱华 | A kind of Bupleurum bupleuri extract, its preparation method and application |
US20160296574A1 (en) * | 2013-11-15 | 2016-10-13 | Osama Mansour Murad | Ephedra alata extracts and methods of use thereof |
EP3079709A1 (en) * | 2013-11-15 | 2016-10-19 | Osama Mansour Murad | Ephedra alata extracts and methods of use thereof |
CN104857043A (en) * | 2014-02-21 | 2015-08-26 | 天津天士力现代中药资源有限公司 | Radix bupleuri extract and preparation method thereof |
CN104839146B (en) * | 2015-05-29 | 2018-02-09 | 广州赛莱拉干细胞科技股份有限公司 | Composition and application thereof, placenta preserve preparation and preparation method thereof |
CN107114356A (en) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | A kind of placenta and umbilical cord cells protect liquid |
CN111096358A (en) * | 2018-10-26 | 2020-05-05 | 湖北文理学院 | Preservation method of Chinese chives |
-
2021
- 2021-12-08 CN CN202111495739.0A patent/CN114190362B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201738373A (en) * | 2016-04-29 | 2017-11-01 | Ultra-Microrigin Biomedical Technology Co Ltd | Placenta active component preparation method for increasing survival rate of stem cells capable of increasing the survival rate of stem cells |
Also Published As
Publication number | Publication date |
---|---|
CN114190362A (en) | 2022-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10251824B2 (en) | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method | |
Gao et al. | Induction and characterization of adventitious roots directly from the explants of Panax notoginseng | |
CN114190362B (en) | A kind of placenta preservation liquid and the preservation method of placenta | |
CN113662985A (en) | Traditional Chinese medicine compound, traditional Chinese medicine effective component composition, compound and application thereof | |
WO2020093510A1 (en) | Separation and purification method for polysaccharide in ganoderma lucidum spores | |
CN104490961A (en) | Preparation method and application of folium apocyni veneti extract | |
KR101565856B1 (en) | Composition for promoting osteogenic differentiation of human mesenchymal stem cells comprising cortex mori radicis extract, patrinia saniculaefolia extract or mixture thereof | |
CN109294980A (en) | Root of kirilow rhodiola and rhodioside are divided into the application in cardiac-like muscle cell in stem cell directional | |
CN119157906B (en) | Umbilical cord mesenchymal stem cell preparation and application thereof in treating liver diseases | |
CN102018718B (en) | Application of Xanthoceraside compound | |
CN118546271A (en) | A kind of roxburghii polysaccharide CLP2-2 and its preparation method and use | |
KR102152394B1 (en) | Composition comprising nucleobases as active ingredients for treating, preventing, or improving Osteoporosis | |
CN109864964B (en) | Anti-aging composition containing stem cells and application thereof | |
CN108324737B (en) | Combination of umbilical cord mesenchymal stem cells for treating hyperglycemia and diabetic nephropathy | |
CN107034253A (en) | A kind of method that use Yunnan rough gentian endogenetic fungus carries out bioconversion | |
CN1331388C (en) | Method for culturing and producing cffeetive ingredients in polyose of saussurca hairy roots of saussurea medusa maxim | |
CN103040915A (en) | Eucommia ulmoides extract and application thereof | |
CN114890931A (en) | Extraction method and application of indole-3-acetonitrile in isati oil | |
CN108210518B (en) | Combination of umbilical cord mesenchymal stem cells for treating hyperglycemia and diabetic nephropathy | |
CN108969548A (en) | The purposes of Bai le leaf total polyphenols | |
CN101647858B (en) | Preparation method of water-soluble extract of red sage root | |
Sangwan et al. | Ribosomal bodies specific to both pollen and zygotic embryogenesis in Datura | |
CN115804343B (en) | Method for synchronously promoting synthesis of hairy root saponins of psammosilene tunicoides and expansion of main roots | |
CN106190837B (en) | A kind of kit and cultural method for cultivating mescenchymal stem cell | |
CN110882236A (en) | Anti-tumor composition, pharmaceutical preparation for treating cancer and application of pharmaceutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |